Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications

被引:263
|
作者
Fechtner, Robert D. [2 ]
Godfrey, David G. [3 ]
Budenz, Donald [4 ]
Stewart, Jeanette A. [1 ]
Stewart, William C. [1 ]
Jasek, Mark C. [5 ]
机构
[1] PRN Pharmaceut Res Network LLC, Dallas, TX 75240 USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Ophthalmol, Newark, NJ 07103 USA
[3] Glaucoma Associates Texas, Dallas, TX USA
[4] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA
[5] Alcon Labs Inc, Ft Worth, TX 76101 USA
关键词
glaucoma; therapy; ocular surface disease; OSDI; prevalence; DRY EYE SYNDROME; OPHTHALMIC EMULSION; DISEASE; EFFICACY; MODERATE; SAFETY;
D O I
10.1097/ICO.0b013e3181c325b2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the prevalence of ocular surface disease (OSD) in patients with glaucoma using topical intraocular pressure (IOP) lowering therapy. Methods: This prospective observational study enrolled patients with primary open-angle glaucoma or ocular hypertension who were on a topical IOP-lowering medication regimen. Enrolled patients completed the ocular surface disease index (OSDI) and SDI scores (0-100, with 0 representing no symptoms) were calculated for each patient. Medical history, demographics, and concomitant medication information were also collected. Results: Overall, 630 patients from 10 sites participated. Of these, 305 patients (48.4%) had an OSDI score indicating either mild (n = 134, 21.3%), moderate (n = 84, 13.3%), or severe (n = 87, 13.8%) OSD symptoms. OSDI scores were significantly different between patients with and without a prior diagnosis of dry eye syndrome (25.2 +/- 15.4 vs 15.4 +/- 15.8, respectively; P = 0.0036) and between patients who did and did not use artificial tears at the time of study participation (23.0 +/- 15.6 vs 15.3 +/- 15.8, respectively; P = 0.0046). Mean OSDI scores varied significantly with the number of topical IOP-lowering medications used, with higher (more severe) OSDI scores in patients using multiple IOP-lowering medications. Specifically, patients on a single medication had a mean OSDI score of 12.9 +/- 13.1, which was significantly lower than those of patients on 2 (16.7 +/- 17.0; P = 0.007) or 3 medications (19.4 +/- 18.1; P = 0.0001). Conclusions: OSD is prevalent among medically treated patients with glaucoma. The severity of OSD symptoms is positively correlated to the number of IOP-lowering medications used.
引用
收藏
页码:618 / 621
页数:4
相关论文
共 50 条
  • [1] The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review
    Asiedu, Kofi
    Abu, Sampson Listowell
    JOURNAL OF CURRENT OPHTHALMOLOGY, 2019, 31 (01): : 8 - 15
  • [2] Prevalence and description of treatment with intraocular pressure-lowering topical medications in continental France
    Delcourt, C.
    Bron, A.
    Baudouin, C.
    Denis, P.
    Nordmann, J. -P.
    Renard, J. -P.
    Rouland, J. -F.
    Sellem, E.
    Stephan, M.
    Levrat, F.
    Solesse, A.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2006, 29 (10): : 1098 - 1106
  • [3] Signs and symptoms of ocular surface disease in patients on topical intraocular pressure-lowering therapy
    Gomes, Beatriz
    de Freitas Turiel, Paulo Romeu
    Marques, Fabiane Pereira
    Bernardo, Fernanda Pessoa
    Abbud Safady, Marcus Vinicius
    Freire Portes, Andre Luos
    Santhiago, Marcony Rodrigues
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2013, 76 (05) : 282 - 287
  • [4] Regression of Neovascularization after Using Only Intraocular Pressure-lowering Medications in Neovascular Glaucoma
    Lee, Sang Wook
    Kim, Ko Eun
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2020, 61 (03): : 307 - 312
  • [5] Intraocular light scatter in patients on topical intraocular pressure-lowering medication
    Perez-Bartolome, Francisco
    Martinez de la Casa, Jose Maria
    Arriola-Villalobos, Pedro
    Fernandez-Perez, Cristina
    Garcia-Feijoo, Julian
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2018, 28 (06) : 652 - 661
  • [6] Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
    Noecker, R.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (11) : 1336 - 1337
  • [7] Long-term effect of canaloplasty on intraocular pressure and use of intraocular pressure-lowering medications in patients with open-angle glaucoma
    Ondrejka, Simon
    Koerber, Norbert
    Dhamdhere, Kavita
    JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2022, 48 (12): : 1388 - 1393
  • [8] Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication
    King, Anthony J.
    Rotchford, Alan P.
    JAMA OPHTHALMOLOGY, 2016, 134 (07) : 742 - 747
  • [9] Should Patients With Optic Disc Drusen Be Treated With Intraocular Pressure-Lowering Medications?
    Falardeau, Julie M.
    Pineles, Stacy L.
    Van Stavern, Gregory P.
    Lee, Andrew G.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2020, 40 (04) : 538 - 543
  • [10] Prevalence and description of treatment with intraocular pressure lowering topical medications in continental France
    Delcout, C
    Bron, A
    Levrat, F
    de Gendre, AS
    VALUE IN HEALTH, 2006, 9 (03) : A140 - A141